Characterisation of an OCS-dependent severe asthma population treated with mepolizumab.
A subpopulation of patients with asthma treated with maximal inhaled treatments is unable to maintain asthma control and requires additional therapy with oral corticosteroids (OCS); a subset of this population continues to have frequent exacerbations. Alternate treatment options are needed as daily use of OCS is associated with significant systemic adverse effects that affect many body systems and have a direct association with the dose and duration of OCS use. We compared the population demographics, medical conditions and efficacy responses of the OCS-dependent group from the DREAM study of mepolizumab with the group not managed with daily OCS.


BACKGROUND
NCT01000506.
GlaxoSmithKline, Research Triangle Park, North Carolina, USA.
C M
CM
Prazma
Division of Pulmonary, Allergy and Critical Care, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
S
S
Wenzel
Respiratory Medical Franchise, GSK, Uxbridge, UK The William Harvey Research Institute, Barts, London, UK The London School of Medicine and Dentistry, London, UK.
N
N
Barnes
Department of Allergy and Immunology, The Royal Melbourne Hospital and The University of Melbourne, Parkville, Victoria, Australia.
J A
JA
Douglass
GlaxoSmithKline, Uxbridge, UK.
B F
BF
Hartley
GlaxoSmithKline, Research Triangle Park, North Carolina, USA.
H
H
Ortega
D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; D061067:Antibodies, Monoclonal, Humanized; C434107:mepolizumab
Asthma; Eosinophil Biology